Yarrow Bioscience Inc

Yarrow Bioscience announced the pricing of an underwritten public offering of 5.77 million shares of common stock at $26.00 per share, for expected gross proceeds of approximately $150 million. The company granted underwriters a 30-day option to purchase up to an additional 865,384 shares. Net proceeds will be used to advance research and development across Yarrow's autoimmune thyroid disease pipeline and to support general corporate purposes, including working capital and capital expenditures. All shares in the offering are being sold directly by Yarrow, and the transaction is scheduled to close on September 14, 2026.

VYNE Therapeutics has distributed its previously announced special cash dividend to stockholders of record as of July 22, 2026, with the payment made on July 23. The company also confirmed that its 1-for-50 reverse stock split is expected to take effect on July 24, after which shares will begin trading on a post-split basis on Nasdaq under a new CUSIP on July 27. The closing of the proposed merger with Yarrow Bioscience, originally anticipated around July 24, is now expected early in the week of July 27, pending final Nasdaq listing approval. Following the merger, the combined company will trade under the name Yarrow Bioscience and the ticker YARW. Due to the dividend exceeding 25% of the stock price at declaration, Nasdaq set the ex-dividend date as July 24, and trades during the due bill period from July 21 through July 23 carry an obligation for sellers to deliver the dividend to buyers.